首页> Nature medicine> Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.

导出 OA

翻译打印收藏纠错

第一作者： Jennifer N,Brudno

第一单位： Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

作者： Jennifer N,Brudno ^[1] ; Norris,Lam ^[1] ; Danielle,Vanasse ^[1] ; Yueh-Wei,Shen ^[2] ; Jeremy J,Rose ^[1] ; John,Rossi ^[2] ; Allen,Xue ^[2] ; Adrian,Bot ^[2] ; Nathalie,Scholler ^[2] ; Lekha,Mikkilineni ^[3] ; Mark,Roschewski ^[4] ; Robert,Dean ^[5] ; Raul,Cachau ^[6] ; Philippe,Youkharibache ^[7] ; Rashmika,Patel ^[8] ; Brenna,Hansen ^[1] ; David F,Stroncek ^[9] ; Steven A,Rosenberg ^[10] ; Ronald E,Gress ^[1] ; James N,Kochenderfer ^[11]

作者单位： Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. ^[1] Kite Pharma, Santa Monica, CA, USA. ^[2] Medical Oncology/Hematology Fellowship Program, NCI, Bethesda, MD, USA. ^[3] Lymphoid Malignancy Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA. ^[4] Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA. ^[5] Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. ^[6] Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[7] Office of Regulatory Affairs, NCI, NIH, Bethesda, MD, USA. ^[8] Center for Cellular Engineering, Clinical Center, NIH, Bethesda, MD, USA. ^[9] Surgery Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA. ^[10] Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. kochendj@mail.nih.gov. ^[11]